Estrella Immunopharma, Inc. (ESLA)
NASDAQ: ESLA · Real-Time Price · USD
1.240
-0.030 (-2.36%)
Dec 30, 2024, 4:00 PM EST - Market closed
Estrella Immunopharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Selling, General & Admin | 2.36 | 3.2 | 0.66 | 0.3 | 0.28 |
| Research & Development | 6.45 | 4.11 | 10.45 | 1.39 | 0.46 |
| Operating Expenses | 8.82 | 7.31 | 11.11 | 1.69 | 0.73 |
| Operating Income | -8.82 | -7.31 | -11.11 | -1.69 | -0.73 |
| Pretax Income | -8.82 | -7.31 | -11.11 | -1.69 | -0.73 |
| Income Tax Expense | 0 | 0 | - | - | - |
| Net Income | -8.82 | -7.31 | -11.11 | -1.69 | -0.73 |
| Preferred Dividends & Other Adjustments | - | - | - | -0.61 | - |
| Net Income to Common | -8.82 | -7.31 | -11.11 | -1.07 | -0.73 |
| Shares Outstanding (Basic) | 36 | 27 | 0 | - | - |
| Shares Outstanding (Diluted) | 36 | 27 | 0 | - | - |
| Shares Change (YoY) | 6450.97% | 8764.81% | - | - | - |
| EPS (Basic) | -0.25 | -0.27 | -36.35 | - | - |
| EPS (Diluted) | -0.25 | -0.27 | -36.35 | - | - |
| Free Cash Flow | -18.01 | -16.07 | -1.34 | -1.44 | -0.67 |
| Free Cash Flow Per Share | -0.50 | -0.59 | -4.37 | - | - |
| EBIT | -8.82 | -7.31 | -11.11 | -1.69 | -0.73 |
Source: S&P Capital IQ. Standard template.
Financial Sources.